L3VLUP
ProSign in

MDGL · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MDGLJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MDGL
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterMDGLJNJ
Q3 20203 holders, $311m30 holders, $26.2bn
Q4 20202 holders, $234m32 holders, $26.6bn
Q1 20214 holders, $281m31 holders, $25.3bn
Q2 20212 holders, $67m37 holders, $25.6bn
Q3 20211 holders, $18m40 holders, $24.1bn
Q4 20211 holders, $19m33 holders, $25.2bn
Q1 20221 holders, $22m35 holders, $28.2bn
Q2 20222 holders, $21m33 holders, $26.9bn
Q3 20222 holders, $14m36 holders, $25.4bn
Q4 20224 holders, $204m35 holders, $27.6bn
Q1 20239 holders, $384m42 holders, $24.5bn
Q2 20235 holders, $589m38 holders, $25.0bn
Q3 20236 holders, $579m37 holders, $18.9bn
Q4 20235 holders, $820m31 holders, $19.0bn
Q1 20248 holders, $1.1bn32 holders, $19.7bn
Q2 20247 holders, $1.1bn35 holders, $20.4bn
Q3 20246 holders, $788m28 holders, $22.3bn
Q4 20246 holders, $1.1bn37 holders, $20.4bn
Q1 20257 holders, $1.2bn32 holders, $20.5bn
Q2 20256 holders, $961m31 holders, $18.4bn
Q3 20259 holders, $1.3bn32 holders, $23.7bn
Q4 202512 holders, $1.8bn29 holders, $27.8bn
Q1 202610 holders, $2.2bn34 holders, $35.6bn
Q2 202611 holders, $2.3bn33 holders, $39.1bn
MDGL

Madrigal Pharmaceuticals Inc

Holders
9
Reported value
$1.3bn
Buyers
6
Sellers
2

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$23.7bn
Buyers
17
Sellers
13

Breadth +4 among 95 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2025

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only MDGL (3)

Artisan Partners LP, Farallon Capital Management LLC, Steadfast Capital Management LP

Only JNJ (26)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →